Policy | August 27, 2025
Indian pharma resilient to US tariffs; Eyes US pricing reform gains: Ind-Ra
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization
Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
Scores highest PAT of Rs. 118 crore in FY25
The National IP Awards recognize outstanding contributions to India’s innovation economy through effective IP creation and commercialization
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Subscribe To Our Newsletter & Stay Updated
